ISCTM 2010 6th Annual Scientific Meeting
Poster Awardees:View posters by clicking on title. |
||
| B. Kasuba, S. Edman: Do Recruitment Sources Impact Study Outcome: Assessment by Computer and Site-Based Raters | ||
| I. Turkoz: "Reporting Adverse Event Data From Clinical Trials of Antipsychotic Agents" | ||
| J. Williams: Placebo Response Assessed by Site and Blinded Remote Centralized Raters in a GAD Trial | ||
| (All poster abstracts are available for public viewing. Link found at end of Day 1) | ||
Day 1 (22 February 2010) |
||
| President’s WELCOME | L Alphs video |
|
| SESSION 1: New Approaches to Assessing the Safety of Marketed Drugs – FDA, Industry and Academic Perspectives SESSION SUMMARY |
Chairs: S Marder M Tohen |
|
| Approaches to Safety Assessment: A Pharmacoepidemiological Perspective | P Wang* | |
| Current Approaches to Pharmaceutical Benefit-Risk Assessment | ||
| Approaches to Marketing Medical Product Safety Assessment: An FDA Perspective | A McMahon (Racoosin) slides |
|
| Panel and General Discussion | C Bowden video |
|
| SESSION 2: Translational and Cultural Adaptation of Key Outcome Measures in International CNS Trials SESSION SUMMARY |
Chairs: A Kalali R Keefe |
|
| The Current Reality of Outcome Measures in International Clinical Trials: Should We Be Doing Things Differently? | ||
| Challenges and Best Practices in Training and Monitoring Measurement of Psychopathology in Linguistically and Culturally Diverse Settings | ||
| Translating and Implementing Measures of Neurocognition in Eastern Europe and Asia | ||
| Cultural Considerations of Functional Outcomes in Chinese and Other Cultures | ||
| Cultural Aspects of Outcome Measures – European and US Regulatory Viewpoints | K Broich video T Laughren video |
|
| Discussant | R Anand slides video |
|
| Poster Session | View All Poster Abstracts |
|
Day 2 (23 February 2010) |
||
| ISCTM 2010 National Mental Health Research-to-Policy Forum: The Role of Comparative Effectiveness Research in Future Mental Health Policy Decision Making |
Chairs: R Ferziger R Manderscheid |
|
| SESSION 3a: The Role of CER in Future Mental Health Policy Decision Making SESSION SUMMARY |
Chair: D Steinwachs |
|
| CER 2010: Overview and Critical Review of the Current Science and Politics of Comparative Effectiveness | ||
|
|
Keynote Address: The Role of CER in Future Mental Health Policy Decision Making | |
| Discussant | J Slutsky slides |
|
| Panel Discussion |
M Schoenbaum |
|
| Relating the Science of CER to Mental Health Policy and Clinical Care |
Chair: B Druss |
|
| Locations, Populations and the Generalizability of Data for Policy Decisions in Mental Health |
R Frank* |
|
| Discussant | M Rawlins slides |
|
| Panel Discussion |
J Parks |
|
| Hitchhikers Guide to System Comparative Effectiveness | ||
| Panel Discussion | video |
|
| SESSION 3b: Comparative Effectiveness Trials in CNS Disorders: Rationale, Elements and Challenges SESSION SUMMARY |
Chairs: N Schooler C Bowden |
|
|
|
What Constitutes Comparative Effectiveness Research? NIH and Inferential Perspectives | |
| Key Issues in CER for Design and Analysis | ||
| Goals and Strategies of the NIMH Recovery After an Initial Schizophrenia Episode (RAISE) Initiative | ||
| The NIMH RAISE Initiative. Two Parallel Approaches to a CER Question: | ||
| Case Study I | ||
| Case Study II | ||
| Academic Discussant |
D Meltzer |
|
| NICE Discussant | ||
| Panel and Participants Discussion | ||
| Summary | ||
| Dinner Symposium: Industry/Academic Relationships: Continuing Collaboration in an Era of Evolving Standards SUMMARY |
Chairs: R Keefe N Schooler |
|
| Principled Research in the Face of Conflicts of Interest | ||
Day 3 (24 February 2010) |
||
| SESSION 4: Clinical Trials in the Prodromal Phase of Alzheimer’s Disease-Methodological Challenges and Clinical Outcomes SUMMARY OF SESSION |
Chairs: G Garibaldi M Davidson |
|
| Challenges Faced when Identifying and Providing Prodromal Disease treatments: The Problems of Preserving Wellness | ||
| Keynote Address: “Antecedent Biomarkers in Prodromal Alzheimer’s Disease – Now is the Time" | ||
| Clinical Correlations with Postmortem Findings: Clues to Identifying the Prodrome for AD-Age Matters | ||
| How Recent Developments in Biomarkers Have Changed Clinical Trials Design-from the Perspective of the Trialist | ||
| Neuroroimaging as a Marker for Prodromal Treatment: Evidence, Value and Limitations | M Cantillon* |
|
| Clinical Trials in Prodromal AD: An Industry Viewpoint | ||
| Prodromal Alzheimer‘s Disease-EU Regulatory Point of View | K Broich slides |
|
| Roundtable Discussion | video |
|
| Adjourn | ||
| * Presentation materials have not been released for posting. | ||